FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023408096> ?p ?o ?g. }

• W2023408096 endingPage "626" @default.
• W2023408096 startingPage "618" @default.
• W2023408096 abstract "We have examined the application of (90)Y-DOTA-cPAM4, anti-MUC1 IgG, in combination with the front-line drug gemcitabine as a potential therapeutic for pancreatic cancer. Athymic nude mice bearing CaPan1 human pancreatic cancer xenografts were administered 2 mg of gemcitabine on days 0, 3, 6, 9 and 12 with concurrent (90)Y-DOTA-cPAM4 (100 microCi) provided on day 0. A second group of mice received a second cycle of treatment 5 weeks after the start of the first cycle. Control groups of mice included those that received either treatment arm alone, the combined modality treatment employing a nontargeting control antibody (hLL2, anti-B-cell lymphoma) and a final group that was left untreated. Gemcitabine administered as a single agent provided no antitumor effect. A single cycle of the combined (90)Y-DOTA-cPAM4 and gemcitabine treatment provided greater inhibition of tumor growth than was observed for any of the other treatment procedures. Tumor growth was delayed for a period of 7 weeks. Two cycles of gemcitabine with concomitant (90)Y-DOTA-cPAM4 yielded significant tumor regression and increased median survival to 21 weeks vs. 12 weeks for mice receiving a single cycle of therapy (p<0.024). Median tumor volume doubling-times were 18 weeks in mice treated with 2-cycles of therapy vs. 7 weeks in mice given only 1-cycle (p<0.001), and 3.5 weeks for the group that received 2-cycles of gemcitabine concomitant with equitoxic nontargeting (90)Y-DOTA-hLL2 (p<0.001). These data suggest that addition of (90)Y-DOTA-cPAM4 RAIT to a gemcitabine treatment regimen may provide enhanced antitumor efficacy for the treatment of pancreatic cancer." @default.
• W2023408096 created "2016-06-24" @default.
• W2023408096 creator A5003932266 @default.
• W2023408096 creator A5018738015 @default.
• W2023408096 creator A5039666197 @default.
• W2023408096 creator A5041414765 @default.
• W2023408096 date "2004-01-01" @default.
• W2023408096 modified "2023-10-17" @default.
• W2023408096 title "Combined90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft" @default.
• W2023408096 cites W1531891842 @default.
• W2023408096 cites W1573890015 @default.
• W2023408096 cites W1859533501 @default.
• W2023408096 cites W1862136029 @default.
• W2023408096 cites W1869307723 @default.
• W2023408096 cites W1892409143 @default.
• W2023408096 cites W1930757563 @default.
• W2023408096 cites W1954948139 @default.
• W2023408096 cites W1966827463 @default.
• W2023408096 cites W1968635539 @default.
• W2023408096 cites W1969877150 @default.
• W2023408096 cites W1976520588 @default.
• W2023408096 cites W1978240169 @default.
• W2023408096 cites W1980026663 @default.
• W2023408096 cites W1980888712 @default.
• W2023408096 cites W1982492189 @default.
• W2023408096 cites W2002815766 @default.
• W2023408096 cites W2011171420 @default.
• W2023408096 cites W2021070333 @default.
• W2023408096 cites W2023189156 @default.
• W2023408096 cites W2026513329 @default.
• W2023408096 cites W2029086462 @default.
• W2023408096 cites W2036963321 @default.
• W2023408096 cites W2041197793 @default.
• W2023408096 cites W2081755626 @default.
• W2023408096 cites W2087650046 @default.
• W2023408096 cites W2091016562 @default.
• W2023408096 cites W2091405318 @default.
• W2023408096 cites W2095584858 @default.
• W2023408096 cites W2098761031 @default.
• W2023408096 cites W2103607678 @default.
• W2023408096 cites W2107990794 @default.
• W2023408096 cites W2109694492 @default.
• W2023408096 cites W2110050868 @default.
• W2023408096 cites W2123185965 @default.
• W2023408096 cites W2129857462 @default.
• W2023408096 cites W2147581636 @default.
• W2023408096 cites W2149546479 @default.
• W2023408096 cites W2165418706 @default.
• W2023408096 cites W2166480410 @default.
• W2023408096 cites W2170263260 @default.
• W2023408096 cites W2256690185 @default.
• W2023408096 cites W2260988755 @default.
• W2023408096 cites W4250448824 @default.
• W2023408096 doi "https://doi.org/10.1002/ijc.20004" @default.
• W2023408096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14991585" @default.
• W2023408096 hasPublicationYear "2004" @default.
• W2023408096 type Work @default.
• W2023408096 sameAs 2023408096 @default.
• W2023408096 citedByCount "50" @default.
• W2023408096 countsByYear W20234080962012 @default.
• W2023408096 countsByYear W20234080962013 @default.
• W2023408096 countsByYear W20234080962014 @default.
• W2023408096 countsByYear W20234080962015 @default.
• W2023408096 countsByYear W20234080962016 @default.
• W2023408096 countsByYear W20234080962017 @default.
• W2023408096 countsByYear W20234080962019 @default.
• W2023408096 countsByYear W20234080962020 @default.
• W2023408096 countsByYear W20234080962021 @default.
• W2023408096 countsByYear W20234080962022 @default.
• W2023408096 crossrefType "journal-article" @default.
• W2023408096 hasAuthorship W2023408096A5003932266 @default.
• W2023408096 hasAuthorship W2023408096A5018738015 @default.
• W2023408096 hasAuthorship W2023408096A5039666197 @default.
• W2023408096 hasAuthorship W2023408096A5041414765 @default.
• W2023408096 hasBestOaLocation W20234080961 @default.
• W2023408096 hasConcept C121608353 @default.
• W2023408096 hasConcept C126322002 @default.
• W2023408096 hasConcept C126894567 @default.
• W2023408096 hasConcept C143998085 @default.
• W2023408096 hasConcept C159654299 @default.
• W2023408096 hasConcept C203014093 @default.
• W2023408096 hasConcept C2776146153 @default.
• W2023408096 hasConcept C2776694085 @default.
• W2023408096 hasConcept C2779384505 @default.
• W2023408096 hasConcept C2780210213 @default.
• W2023408096 hasConcept C2780258809 @default.
• W2023408096 hasConcept C542903549 @default.
• W2023408096 hasConcept C71924100 @default.
• W2023408096 hasConceptScore W2023408096C121608353 @default.
• W2023408096 hasConceptScore W2023408096C126322002 @default.
• W2023408096 hasConceptScore W2023408096C126894567 @default.
• W2023408096 hasConceptScore W2023408096C143998085 @default.
• W2023408096 hasConceptScore W2023408096C159654299 @default.
• W2023408096 hasConceptScore W2023408096C203014093 @default.
• W2023408096 hasConceptScore W2023408096C2776146153 @default.
• W2023408096 hasConceptScore W2023408096C2776694085 @default.
• W2023408096 hasConceptScore W2023408096C2779384505 @default.
• W2023408096 hasConceptScore W2023408096C2780210213 @default.

• next